Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 17/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 17/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 16/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 15/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 14/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950826 | 0.89 | GABRG2 (0.61) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL341741 | 0.82 | GABRG2 (0.62) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL341055 | 0.80 | GABRA1 (0.63) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL340896 | 0.79 | GABRA1 (0.78) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL341650 | 0.79 | GABRG2 (0.67) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL5799755 | 0.79 | GABRG2 (0.67) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL342027 | 0.78 | GABRA1 (0.69) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL340744 | 0.78 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6040307 | 0.78 | GABRA1 (0.68) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL340621 | 0.77 | GABRA1 (0.66) | GABRG2GABRB3GABRA3GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915875-B1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2003-04-09 | — | — | EP | claimed |
| US-6174886-B1 | TREATMENT AND/OR PREVENTION OF PSYCHOTIC DISORDERS INCLUDING SCHIZOPHRENIA WITH REDUCED SEDATION; SELECTIVE LIGANDS FOR GAMMA-AMINOBUTYRIC ACID A RECEPTORS, IN PARTICULAR HAVING HIGH AFFINITY FOR THE ALPHA2 AND/OR ALPHA3 SUBUNIT | MERCK SHARP & DOHME LTD. (GB) | 2001-01-16 | — | — | US | claimed |
| US-6063783-A | Analgesic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-05-16 | — | — | US | claimed |
| US-6046196-A | Antispastic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | claimed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | claimed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | claimed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | claimed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097625-B2 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | SUNOVION PHARMACEUTICALS INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1696959-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1047427-A1 | COMBINATION OF A GABA-A ALPHA 2/3 AGONIST AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR | MERCK SHARP & DOHME LTD. (GB) | 2000-11-02 | — | — | EP | disclosed |
| US-6110915-A | Antiemetic use of triazolo-pyridazine derivatives | MERCK & CO., INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6107296-A | Neuroprotective use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| US-6063783-A | Analgesic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-05-16 | — | — | US | disclosed |
| US-6046196-A | Antispastic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | disclosed |
| WO-1999037303-A1 | COMBINATION OF A GABA-A ALPHA 2/3 AGONIST AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR | MERCK SHARP & DOHME LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABRG2 94/4885GABRB3 100/4885GABRA3 60/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABRG2 97/4885GABRB3 85/4885GABRA3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.